InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017

events
Conference
May 23, 2017

Moscow, Russia - May 23, 2017. InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017. He will speak about how to use QSP modeling to investigate drug safety at different stages of development.

Oleg will describe two case studies from the InSysBio practice in his report. The first one concerns Familial Mediterranean Fever (FMF) therapy, which is being developed by R-Pharm pharmaceutical company (Russia). A new drug, which is a protein that binds several mediators of the disease, is now undergoing clinical trials. R-Pharm provided data on preclinical studies on monkeys, and the task of the InSysBio team was to predict the minimal effective dose for human trials, which means striking a balance between efficacy and safety. You will learn from Oleg Demin's presentation how the InSysBio team met this challenge with the help of systems pharmacology tools.

The second case shows how QSP modeling helped to explain the mechanisms of eosinophilia in patients receiving a specific anti-asthma therapy.It is known that an increase in the number of blood eosinophils under asthma pathology is a marker of inflammation. Therefore drugs causing a similar effect were considered not to be safe. However, with the help of system pharmacology modeling, the group led by Tatyana Karelina showed that the substance was not only safe but also effective, and eosinophilia in blood was a consequence of a decrease in inflammation in lungs. You can read more about this case here.

At the end of his report Oleg will present the latest InSysBio scientific developments. He will talk about cutting-edge modeling methods for immunological diseases and medications. In this field it is very dangerous to choose the wrong dose or target: several cases of patients’ deaths at the first stages of clinical trials are known. That's why pharmaceutical companies need to get exact predictions for immune drug development. Come and listen to Oleg's speech about methods for cell dynamics modeling in immunology May 24, 2017 on section Systems pharmacology – innovative approaches to drug safety, Stockholm, Sweden.

November 2021
MoTuWeThFrSaSu
1
2
3
4
5
6
7
8
9
10
1. 10 Nov 2021 20:48 InSysBio to take part in ACoP12 InSysBio announces its participation in Twelfth American Conference on Pharmacometrics (ACoP12) which is to be held in virtual format this year from November 8-12, 2021. The theme of ACoP12 is “Charting the Course for Our Future”. InSysBio team is going to present the update at its Virtual Booth and 12 posters in frames of the Conference
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1. 30 Nov 2021 15:17 The new website represents InSysBio’s diverse expertise and corporate philosophy InSysBio announces the launch of its new website. The aim of redesign was to fully represent all InSysBio’s diversified experience and to reflect the company’s current trend. The new website is more structured, user-friendly and provides more opportunities for feedback.
     
Upcoming Events
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator